Search Results - M.A. Proskurin

  • Showing 1 - 14 results of 14
Refine Results
  1. 1
    Pharmacoeconomical analysis of use of the low-molecular weight heparins for prevention of the venous tromboembolism in the conditions of multidisciplinary hospital

    Pharmacoeconomical analysis of use of the low-molecular weight heparins for prevention of the venous tromboembolism in the conditions of multidisciplinary hospital by A. S. Kolbin, I. A. Vilyum, M. A. Proskurin, Yu. E. Balykina

    Published 2015-03-01
    Get full text
    Article

    Save to List
    Saved in:
  2. 2
    PHARMACOECONOMIC ANALYSIS OF THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD

    PHARMACOECONOMIC ANALYSIS OF THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD by A. S. Kolbin, I. A. Vilum, Yu. E. Balykina, M. A. Proskurin

    Published 2015-03-01
    Get full text
    Article

    Save to List
    Saved in:
  3. 3
    HEALTH ECONOMIC ASSESSMENT OF ANTIRHEUMATIC DRUGS IN PATIENTS WITH REUMATHOID ARTHRITIS PROGRESSED AFTER METOTREXATE

    HEALTH ECONOMIC ASSESSMENT OF ANTIRHEUMATIC DRUGS IN PATIENTS WITH REUMATHOID ARTHRITIS PROGRESSED AFTER METOTREXATE by A. S. Kolbin, A. A. Kurylev, M. A. Proskurin, Yu. E. Balykina

    Published 2016-12-01
    Get full text
    Article

    Save to List
    Saved in:
  4. 4
    PHARMACOECONOMIC ANALYSIS OF MICAFUNGIN USING IN THE TREATMENT OF INVASIVE CANDIDIASIS IN NEWBORNS

    PHARMACOECONOMIC ANALYSIS OF MICAFUNGIN USING IN THE TREATMENT OF INVASIVE CANDIDIASIS IN NEWBORNS by A.S. Kolbin, M.A. Proskurin, Yu.A. Balykina, N.N. Klimko

    Published 2011-08-01
    Get full text
    Article

    Save to List
    Saved in:
  5. 5
    BUDGET IMPACT ANALYSIS IN THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD

    BUDGET IMPACT ANALYSIS IN THE USE OF RIBOMUSTIN® IN THERAPY OF THE FIRST LINE OF A MULTIPLE MYELOMA FOR PATIENTS MORE SENIOR 65 YEARS OLD by A. S. Kolbin, I. A. Vilyum, M. A. Proskurin, Yu. E. Balykina

    Published 2015-06-01
    Get full text
    Article

    Save to List
    Saved in:
  6. 6
    Efficacy of alectinib in comparison with lorlatinib in patients with ALK-positive non-small cell lung cancer: pharmacoeconomic study

    Efficacy of alectinib in comparison with lorlatinib in patients with ALK-positive non-small cell lung cancer: pharmacoeconomic study by A. S. Kolbin, Yu. M. Gomon, M. A. Proskurin, Yu. E. Balykina

    Published 2023-11-01
    Get full text
    Article

    Save to List
    Saved in:
  7. 7
    Pharmacoeconomic analysis of fixed-duration targeted therapy regimens for chronic lymphocytic leukemia compared with therapy used until progression or intolerable toxicity

    Pharmacoeconomic analysis of fixed-duration targeted therapy regimens for chronic lymphocytic leukemia compared with therapy used until progression or intolerable toxicity by A. R. Kasimova, A. S. Kolbin, M. A. Proskurin, Yu. E. Balykina

    Published 2022-11-01
    Get full text
    Article

    Save to List
    Saved in:
  8. 8
    Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia

    Pharmacoeconomic analysis of using typical and atypical antipsychotics in schizophrenia by I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina

    Published 2018-08-01
    Get full text
    Article

    Save to List
    Saved in:
  9. 9
    Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia

    Pharmacoeconomic assessment of antipsychotic treatment in outpatients with schizophrenia by I. A. Vilyum, B. V. Andreev, M. A. Proskurin, Yu. E. Balykina

    Published 2018-05-01
    Get full text
    Article

    Save to List
    Saved in:
  10. 10
    The socioeconomic burden of meningococcal infection in the Russian Federation

    The socioeconomic burden of meningococcal infection in the Russian Federation by Yu. V. Lobzin, A. S. Kolbin, A. A. Vilnits, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin

    Published 2024-12-01
    Get full text
    Article

    Save to List
    Saved in:
  11. 11
    Modeling microbial drug-resistance: from mathematics to pharmacoeconomics

    Modeling microbial drug-resistance: from mathematics to pharmacoeconomics by Yu. M. Gomon, M. A. Arepyeva, Yu. E. Balykina, A. S. Kolbin, A. A. Kurylev, M. A. Proskurin, S. V. Sidorenko

    Published 2018-05-01
    Get full text
    Article

    Save to List
    Saved in:
  12. 12
    FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS

    FIRST RUSSIAN TYPE 2 DIABETES MELLITUS SIMULATION MODEL WITH DISCREET EVENTS MODELING. HEALTH-ECONOMIC ANALYSIS by A. S. Kolbin, O. K. Khmelnitskiy, A. A. Kurylev, Yu. E. Balykina, M. A. Proskurin, E. P. Kolpak, M. V. Bure

    Published 2015-03-01
    Get full text
    Article

    Save to List
    Saved in:
  13. 13
    The social-economic burden of spinal muscular atrophy in Russia

    The social-economic burden of spinal muscular atrophy in Russia by A. S. Kolbin, D. V. Vlodavets, A. A. Kurylev, Yu. Ye. Balykina, M. A. Proskurin, S. A. Mishinova, O. Yu. Germanenko, N. Yu. Kolbina

    Published 2021-02-01
    Get full text
    Article

    Save to List
    Saved in:
  14. 14
    ANALYSIS OF CONSUMPTION OF ANTIBACTERIAL DRUGS FOR SYSTEMIC USE IN HOSPITALS OF SAINT PETERSBURG IN 2014–2015

    ANALYSIS OF CONSUMPTION OF ANTIBACTERIAL DRUGS FOR SYSTEMIC USE IN HOSPITALS OF SAINT PETERSBURG IN 2014–2015 by Yu. M. Gomon, A. A. Kurylev, A. S. Kolbin, M. A. Proskurin, I. G. Ivanov, S. V. Sidorenko, M. A. Arepieva, A. V. Sokolov

    Published 2018-10-01
    Get full text
    Article

    Save to List
    Saved in:

Search Tools: